Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002090:Butyrophenones / Q000494:pharmacology*; D055598:Chemical Phenomena; D002621:Chemistry; D002746:Chlorpromazine / Q000494:pharmacology; D003984:Dibenzazepines / Q000494:pharmacology; D005116:Extrapyramidal Tracts / Q000187:drug effects*; D005476:Fluphenazine / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D000882:Haplorhini; D006801:Humans; D010546:Perphenazine / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology; D011395:Promazine / Q000494:pharmacology; D051381:Rats; D011950:Receptors, Cholinergic / Q000187:drug effects*; D012559:Schizophrenia / Q000188:drug therapy; D013881:Thioridazine / Q000494:pharmacology; D014273:Triflupromazine / Q000494:pharmacology
D014150:Antipsychotic Agents; D002090:Butyrophenones; D003984:Dibenzazepines; D010640:Phenothiazines; D011950:Receptors, Cholinergic; D010546:Perphenazine; D006220:Haloperidol; D013881:Thioridazine; D011395:Promazine; D014273:Triflupromazine; D005476:Fluphenazine; D002746:Chlorpromazine